Table 3.
Total number of HFMD case reduction in I3* under different coverage scenarios over 1 year
| Bivalent vaccine coverage | EV-71 vaccine coverage | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0% | 10% | 30% | 50% | 80% | ||||||
| Case reduction (%**) | NNV*** | Case reduction (%) | NNV | Case reduction (%) | NNV | Case reduction (%) | NNV | Case reduction (%) | NNV | |
| 0% | 0(0.0) | – | 123,776(7.6) | 77.6 | 339,672(20.9) | 84.8 | 537,032(33.0) | 89.4 | 797,262(49.1) | 96.3 |
| 10% | 130,639(8.0) | 73.5 | 240,476(14.8) | 79.8 | 446,345(27.5) | 86.0 | 633,389(39.0) | 90.9 | 877,700(54.0) | 98.4 |
| 30% | 357,871(22.0) | 80.5 | 457,647(28.2) | 83.9 | 642,969(39.6) | 89.6 | 808,968(49.8) | 94.9 | 1,021,084(62.8) | 103.4 |
| 50% | 563,164(34.7) | 85.2 | 652,564(40.2) | 88.3 | 816,793(50.3) | 94.0 | 961,374(59.2) | 99.9 | 1,141,319(70.2) | 109.3 |
| 80% | 828,560(51.0) | 92.7 | 901,989(55.5) | 95.8 | 1,034,085(63.6) | 102.1 | 1,146,680(70.6) | 108.8 | 1,280,602(78.8) | 119.9 |
| 100% | 976,602(60.1) | 98.3 | 1,039,339(63.9) | 101.6 | 1,150,320(70.8) | 108.5 | 1,242,653(76.5) | 115.9 | 1,349,720(83.0) | 128.0 |
*I3 indicates the number of EV71 or CVA16 HFMD / only EV71- HFMD , based on different types of vaccines.
**%: The percentage of the number of HFMD case reduction in I3 based on the initial number with no intervention
***NNV The number of persons needed to be vaccinated per case reduction